@entity5506 in XXXX .

@entity1 @entity784 @entity1872 @entity9466 @entity281 @entity1200 @entity5506 @entity74 @entity2142 @entity288
@entity9466 is an @entity1200 characterized by @entity784 and chronic superficial @entity281 . We report on three @entity1 with @entity9466 who developed autoantibodies to erythrocytes. Our first @entity1 , a 19-year-old female, developed @entity5506 ( @entity5506 ) that required multiple courses of treatment, including corticosteroids, intravenous immunoglobulin, and @entity1872 . During the last exacerbation of @entity5506 , intensive treatment with @entity288 and intravenous immunoglobulin failed and yet the @entity1 responded to plasmapheresis. Our second @entity1 , a 21-year-old male, developed @entity5506 which responded to oral corticosteroid therapy. Our third @entity1 , a 6-year-old female without evidence of @entity2142 , was found to have erythrocyte autoantibodies on routine screening. These three @entity1 had positive direct antiglobulin tests, and the first @entity1 had both immunoglobulin G (IgG) and IgM erythrocyte autoantibodies, while the remaining two @entity1 had only IgG autoantibody. This is the first report of the association of @entity5506 with @entity9466 . We suggest that all @entity1 with @entity9466 be screened periodically for erythrocyte autoantibodies. Plasmapheresis, a safe ancillary procedure in the management of @entity5506 , may be life-saving in some cases. The occurrence of erythrocyte autoantibodies in @entity9466 may be related to @entity74 in this disease.
